NCT07365280 — ZSky Biotech neoantigen vaccine trial
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
Registry record
| Registry ID | NCT07365280 ↗ |
|---|---|
| Lead sponsor | ZSky Biotech Inc |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Not Yet Recruiting |
| Indication | Glioblastoma |
| Enrollment | 78 participants (target) |
| Start date | 2026-01-09 |
| Primary completion | 2028-12-24 (est.) |
| Last registry update | 26 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07365280), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07365280?
NCT07365280 (Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma) is registered on ClinicalTrials.gov as Phase 2, sponsored by ZSky Biotech Inc.
Is NCT07365280 recruiting?
As of the 2026-01-26 registry update, NCT07365280 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07365280?
The lead sponsor is ZSky Biotech Inc.
What condition does NCT07365280 study?
The registered condition is Glioblastoma. Primary completion is listed as 2028-12-24 (estimated).
Are results available for NCT07365280?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07365280.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.